Aktienanalyse zu Matinas BioPharma Holdings Inc (MTNB)MTNBMatinas BioPharma Holdings Inc

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Matinas BioPharma Holdings Inc is not a good buy right now. The current price is $1.25, with an RSI of 25.709 indicating oversold conditions, but the company has reported a staggering year-to-date change of -86.56% and a negative forward P/E ratio of 0, reflecting a lack of profitability and growth potential. Additionally, the company faces delisting risk from the NYSE due to insufficient shareholder equity, which is currently at $1.8 million, below the required $2 million. This financial instability poses a significant risk for investors.

3 analysts cover MTNB: 3 rate it Buy, 0 Hold and 0 Sell.